• Melek Karabacak, İjlal Erturan, Kuyaş Hekimler Öztürk, Havva Hilal Ayvaz, Selma Korkmaz, Mehmet Yıldırım, and Hikmet Orhan.
• Department of Dermatology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey
• Turk J Med Sci. 2021 Jun 28; 51 (3): 1098-1105.

Background/AimAlthough the cause of immune activation in the pathogenesis of psoriasis is still unclear, miRs are thought to have an effect on psoriasis. This work aimed to evaluate the role of miRs (miR-4649-3p, miR-6867-5p, miR-4296, miR-210, and miR-1910-3p) that target the FOXP3 mRNA and IL-17A mRNA in psoriasis.Materials And MethodsForty-four psoriasis patients and 44 healthy controls were included in the study. Quantitative real-time PCR (qRT-PCR) was used for the measurement of miRs. Serum IL-17A levels were determined by an enzyme-linked immunosorbent assay (ELISA) method.ResultsPlasma miR-1910-3p levels were significantly lower in the patient group than the controls (P = 0.000, fc: 0.10). ROC analysis showed that plasma miR-1910-3p levels could significantly differentiate psoriasis patients from healthy controls [AUC = 0.912 (0.848– 0.975), P = 0.000]. The plasma miR-4649-3p level was significantly higher in the psoriasis group compared to the controls (P = 0.000, fc: 2.99).ConclusionDecreased expression of miR-1910-3p increases the risk of developing psoriasis by approximately 50-fold and was able to use for the significant differentiation of psoriatic patients from healthy controls.This work is licensed under a Creative Commons Attribution 4.0 International License.

13 keywords...

hide…